- Home
- BTAI vs MCVT Comparison
BTAI vs MCVT Comparison
Compare BTAI & MCVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- MCVT
- Stock Information
- Founded
- BTAI 2017
- MCVT 2007
- Country
- BTAI United States
- MCVT United States
- Employees
- BTAI N/A
- MCVT N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- MCVT Finance Companies
- Sector
- BTAI Health Care
- MCVT Finance
- Exchange
- BTAI Nasdaq
- MCVT Nasdaq
- Market Cap
- BTAI 8.3M
- MCVT 9.3M
- IPO Year
- BTAI 2018
- MCVT N/A
- Fundamental
- Price
- BTAI $1.86
- MCVT $1.80
- Analyst Decision
- BTAI Buy
- MCVT
- Analyst Count
- BTAI 5
- MCVT 0
- Target Price
- BTAI $34.60
- MCVT N/A
- AVG Volume (30 Days)
- BTAI 295.5K
- MCVT 16.1K
- Earning Date
- BTAI 08-05-2025
- MCVT 08-13-2025
- Dividend Yield
- BTAI N/A
- MCVT N/A
- EPS Growth
- BTAI N/A
- MCVT N/A
- EPS
- BTAI N/A
- MCVT 0.19
- Revenue
- BTAI $1,852,000.00
- MCVT $3,246,479.00
- Revenue This Year
- BTAI $5.03
- MCVT N/A
- Revenue Next Year
- BTAI $291.01
- MCVT N/A
- P/E Ratio
- BTAI N/A
- MCVT $9.65
- Revenue Growth
- BTAI 5.47
- MCVT N/A
- 52 Week Low
- BTAI $1.17
- MCVT $1.13
- 52 Week High
- BTAI $21.92
- MCVT $3.88
- Technical
- Relative Strength Index (RSI)
- BTAI 56.60
- MCVT 45.83
- Support Level
- BTAI $1.69
- MCVT $1.78
- Resistance Level
- BTAI $2.08
- MCVT $1.92
- Average True Range (ATR)
- BTAI 0.21
- MCVT 0.08
- MACD
- BTAI 0.02
- MCVT -0.02
- Stochastic Oscillator
- BTAI 57.89
- MCVT 11.11
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About MCVT Mill City Ventures III Ltd.
Mill City Ventures III Ltd is a non-bank lender and specialty finance company. The company is engaged in the business of providing short-term specialty finance solutions to private businesses, micro-and small-cap public companies, and high-net-worth individuals. The principal specialty finance solutions that the group provides are high-interest short-term lending arrangements. Typically, these lending arrangements involve obtaining collateral as security for the borrower's repayment of funds, or personal guarantees from the principals or affiliates of the borrower.